<DOC>
	<DOCNO>NCT01630850</DOCNO>
	<brief_summary>The purpose study learn safety islet transplantation Type 1 diabetes mellitus , may provide normal control blood sugar without need insulin shot . Islets special cluster cell within pancreas produce insulin . These cell obtain cadaver ( non-living ) donor give subject vein .</brief_summary>
	<brief_title>Islet Transplantation Patients With `` Brittle '' Type I Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<criteria>Male female patient 18 70 year age . Subjects able provide write informed consent comply procedure study protocol . Clinical history compatible T1D onset disease &lt; 40 year age , insulindependence ≥ 5 year time enrollment , sum patient age insulin dependent diabetes duration ≥ 28 . Absent stimulate cpeptide ( &lt; 0.3ng/mL ) response mixed meal tolerance test ( MMTT ; Boost® 6 mL/kg body weight maximum 360 mL ; another product equivalent caloric nutrient content may substitute Boost ) measure 60 90 min start consumption . Involvement intensive diabetes management define self monitor glucose value less mean three time day average week administration three insulin injection day insulin pump therapy . Such management must direction endocrinologist , diabetologist , diabetes specialist least 3 clinical evaluation 12 month prior study enrollment . At least one episode severe hypoglycemia 12 month prior study enrollment . Reduced awareness hypoglycemia define Clarke score 4 OR HYPO score great equal 90th percentile ( 1047 ) screen period within last 6 month ; OR mark glycemic lability characterize wide swing blood glucose despite optimal diabetes therapy define LI score great equal 90th percentile ( 433 mmol/L2/h wk1 ) screening period within last 6 month prior randomization ; OR composite Clarke score 4 HYPO score great equal 75th percentile ( 423 ) LI great equal 75th percentile ( 329 ) screening period within last 6 month . Body mass index ( BMI ) &gt; 30 kg/m2 patient weight &lt; 50kg . Insulin requirement &gt; 1.0 IU/kg/day &lt; 15 U/day . HbAlc &gt; 10 % . Untreated proliferative diabetic retinopathy . Blood Pressure : SBP &gt; 160 mmHg DBP &gt; 100 mmHg . Measured glomerular filtration rate &lt; 80 mL/min/1.73m2 ( use iohexol calculate use subject 's measure serum creatinine Chronic Kidney Disease Epidemiology Collaboration ( CKDEPI equation ) base 24hrs urine collection . Strict vegetarian ( vegan ) calculate GFR &lt; 70 mL/min/1.73m2 exclude . The absolute ( raw ) GFR value use subject body surface area &gt; 1.73 m2 . Presence history macroalbuminuria ( &gt; 300 mg/g creatinine ) . Presence history panelreactive antiHLA antibody 30 % history/presence donor specific antiHLA antibody order avoid unacceptable antigen ( ) ( Campbell PM 2007 ) . For female subject : Positive pregnancy test , presently breastfeed , unwillingness use effective contraceptive measure duration study 4 month discontinuation . For male subject : intent procreate duration study within 4 month discontinuation unwillingness use effective measure contraception . Oral contraceptive , Norplant® , DepoProvera® , barrier device spermicide acceptable contraceptive method ; condom use alone acceptable . Presence history active infection include hepatitis B , hepatitis C , HIV , tuberculosis ( TB ) . Subjects laboratory evidence active infection exclude even absence clinical evidence active infection . Known active alcohol substance abuse . Severe coexist cardiac disease Known hypercoagulative state . Symptomatic cholecystolithiasis . Acute chronic pancreatitis . Other protocol relate inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>